OBJECTIVE: To investigate the effects of hyperglycaemia and hyperinsulinaemia on amino acid disposal in human obesity. DESIGN: Four sequential experimental conditions: (1) overnight fasting; (2) hyperglycaemia with hyperinsulinaemia (2 h hyperglycaemic clamp at 11 mmolal); (3) hyperglycaemia with basal insulin (1 h hyperglycaemic clamp during somatostatin infusion), (4) hyperglycaemia with resuming hyperinsulinaemia (1 h hyperglycaemic clamp after somatostatin discontinuation). SUBJECTS: Seven non-obese and seven obese non-diabetic, normo-insulinaemic subjects. MEASUREMENTS: Glucose infused to maintain steady-state hyperglycaemia. Plasma insulin, glucagon, free fatty acid and amino acid concentrations in the last 20 min of the four experimental conditions. Net rates of plasma amino acid disappearance and appearance (m mmolal per hour), calculated as the slopes of the regression of amino acid concentration on time. RESULTS: The amount of glucose infused to maintain hyperglycaemia was reduced by nearly 50% in obese subjects. During hyperinsulinaemia, FFA suppression was lower in obese subjects. In all experimental conditions plasma amino acid levels were slightly, non-signi®cantly higher in obese than in non-obese subjects. In both groups plasma amino acids decreased slightly with ongoing fasting, decreased remarkably during hyperglycaemia ± hyperinsulinaemia, rose promptly when insulin concentration was suppressed by somatostatin infusion, and declined again after somatostatin discontinuation. Also the time-course of plasma branched-chain amino acids, which paralleled that of total amino acids, was similar in the two groups. The net rates of amino acid disappearance from plasma did not differ in obese and non-obese subjects both at fasting and during hyperglycaemia ± hyperinsulinaemia. Also plasma amino acid appearance during hyperglycaemia with basal insulin was not different in the two groups. CONCLUSION: The net traf®c of amino acids to and from plasma in relation to insulin drive and prevailing glucose is not impaired in obese subjects with normal glucose tolerance, in spite of a decreased insulin sensitivity of glucose and lipid metabolism.
Introduction
Substrate availability and competition, hormone concentration and hormone sensitivity interact in the disposal of glucose, free fatty acids (FFA) and amino acids to provide substrates and energy for biological processes. 1 Insulin resistance of glucose metabolism is a well known feature of human obesity, 2, 3 often responsible for impaired glucose tolerance or frank diabetes. 4 Glucose disposal during both euglycaemic 5, 6 and hyperglycaemic 7 hyperinsulinaemia is reduced in obese subjects, also in the presence of a normal glucose tolerance. 8 Also insulin action on FFA metabolism is impaired in human obesity, 3 although this metabolic defect can be generally appreciated only at low concentrations of the hormone. 9 Insulin is also known to regulate plasma amino acids concentrations in a dose-dependent manner, 10 and branched-chain amino acid (BCAA) levels are particularly sensitive to insulin. 11 However, con¯ict-ing data have been reported on the effects of obesityassociated hyperinsulinaemia andaor insulin resistance on plasma amino acid concentrations in the fasting state 12 ± 14 and following oral or i.v. glucose administration. 12, 15, 16 As to the euglycaemic hyperinsulinaemic condition, the plasma disappearance of BCAA was shown to be reduced in obesity in relation to the degree of insulin resistance. 14 Basal leucine turnover, an index of proteolysis, was found to be increased 17 ± 19 or unaltered 20 ± 23 in obese subjects. Finally, inconsistent data were reported on the insulin effect on protein metabolism in obese subjects. 17, 19, 23, 24 It has been suggested that hyperglycaemia stimulates protein breakdown, 25 and a direct role for fasting and post-meal hyperglycaemia in the regulation of plasma amino acid concentrations in obesity was previously proposed. 16 However, data on the effect of hyperglycaemia on amino acid metabolism are sparse and inconclusive. Furthermore, most previous studies on amino acid disposal in obesity did not control for differences in prevailing glucose and insulin concentrations.
The present study was initiated to evaluate the effects of hyperglycaemia with and without hyperinsulinaemia on plasma concentrations of amino acids in obese patients. Care was taken to ensure a steady level of hyperglycaemia and a controlled level of insulinaemia (basal, high), with similar plasma concentrations of substrates and the hormones in obese and non-obese subjects.
Materials and methods

Patients
Seven non-obese, non-diabetic subjects (age 30 s.d. 6 y; range 24 ± 39; ®ve males, two pre-menopausal females), and seven obese subjects (age 41 (8) y; range 27 ± 54, two males, ®ve pre-menopausal females) were studied. Their body mass index averaged 22.2 (3.5) and 36.4 (3.5) kgam 2 respectively (range in obese subjects, 31.6 ± 43.7). Obese subjects were selected on the basis of a normal oral glucose tolerance by standard criteria 4 and normoinsulinaemia during the glucose load (peak insulin concentrations not exceeding 100 mUaml), in the attempt to match groups for their insulin response during hyperglycaemic clamp studies.
All subjects had normal hepatic and renal function, and had not been on drug, diet or exercise programs in the previous 3 months. They gave informed consent to the study, which was approved by the local Ethical Committee.
Methods
In the morning, after an overnight fast, each subject underwent a 4 h hyperglycaemic glucose clamp carried out according to the method described by DeFronzo et al. 26 Brie¯y, after a 30-min baseline evaluation, plasma glucose concentrations were acutely raised to approximately 11 mmolal by a priming glucose infusion, and a steady-state hyperglycaemia was then maintained at end-priming values for a total of 4 h by a variable glucose infusion. Mean glucose concentrations during the period 20 ± 240 min of the clamp studies was stable (coef®cient of variation, 9% in non-obese and 7% in obese subjects), and was not different between groups. Synthetic cyclic somatostatin-14 (Stilamin 1 , Serono, Rome, Italy) was infused during the third hour of the study (from 120 to 180 min) at a rate of 2.5 nmolamin (250 mgah) to inhibit glucose-stimulated insulin release. Therefore, we had four sequential experimental conditions: (1) overnight fasting (basal period); (2) hyperglycaemia and hyperinsulinaemia (2 h hyperglycaemic clamp, period A); (3) hyperglycaemia at basal insulin (1 h hyperglycaemic clamp associated with somatostatin infusion, period B); (4) hyperglycaemia and resuming hyperinsulinaemia (1 h hyperglycaemic clamp following somatostatin discontinuation, period C).
Blood samples were obtained from an antecubital vein 30, 20 and 10 min before starting the glucose infusion and then at 10 min intervals throughout periods A, B and C for plasma glucose, free fatty acids (FFA), insulin and glucagon measurements. Plasma samples collected in the basal period, and in the last 20 min of periods A, B and C, were also used for amino acid determination. Samples were kept frozen at À20 C until analysis. Glucose was measured by the glucose oxidase technique. Insulin and glucagon were measured by standard double antibody radioimmunoassays. Plasma amino acid concentrations were determined with a 3A30 Carlo Erba Amino Analyser (Carlo Erba-Fisons, Rodano, Milan, Italy), using the method described previously. 27 All the samples of each subject were run within the same assay. In our laboratory, the intraassay and inter-assay coef®cients of variation in the determination of plasma amino acids were within AE 5% and AE 10%, respectively. The total content of amino acids in plasma was calculated as the sum of individual free amino acids.
Statistical analysis
All analyses were carried out on a personal computer with StatView II 2 program (Abacus Concepts Inc., Berkeley, CA).
Hormone and substrate concentrations measured at baseline and in the last 20 min of each period were averaged, and mean values were considered for statistical purposes. Amino acid concentrations measured between time À30 and À10 min (basal period) were used to calculate the basal net rate of disappearance of individual amino acids (mmolal per hour), as the slope of the regression of amino acid concentration on time. Similarly, amino acid values obtained in the last 20 min of periods A, B and C were used to calculate their net rate of appearance or disappearance in the presence of hyperglycaemia and hyperinsulinaemia (period A), hyperglycaemia and basal insulin concentrations (period B) and in the course of hyperglycaemia with resuming hyperinsulinaemia, and moderate hypoaminoacidaemia (period C).
Glucose, FFA, insulin and glucagon concentrations in the two groups and in the four experimental conditions were analysed for signi®cance by means of Student's t-test for paired and unpaired data. Rates of amino acid appearance and disappearance were tested for signi®cance by means of a two-way analysis of variance (ANOVA) for repeated measurements, with time and group as independent variables. Since Plasma amino acid levels in obese subjects G Marchesini et al three sets of variables were simultaneously tested (hormones, amino acids and clamp-derived parameters), the limit of signi®cance was reduced according to Duncan's multiple range 28 P H 1 À nÀ1 p 1 À P, where P 0.05 and n 3. The ®nal critical value of signi®cance was set at 0.025.
Results
Plasma glucose concentration were not different in obese and non-obese subjects in the basal state and during steady-state hyperglycaemia (Table 1) . During the hyperglycaemic clamp, insulin levels increased, and in the last 20 min of period A and C they were on average 4 ± 5-fold higher than in the basal state, without differences between groups. In period B, when somatostatin infusion was superimposed, insulin fell to basal values in both groups. Plasma glucagon was moderately suppressed (about 50%) during hyperglycaemia with hyperinsulinaemia (periods A and C), and remarkably so (more than 90%) during somatostatin infusion (period B). Plasma FFA concentrations were higher in obese subjects throughout the study periods (Table 1) , in agreement with the increased fat mass of these patients. The percent reduction of FFA during hyperinsulinaemia was signi®cantly lower in obese subjects. The amount of glucose infused and metabolized to maintain steady-state hyperglycaemia (M) was signi®cantly lower in obese subjects throughout all study periods. The index of insulin sensitivity (Mainsulin), calculated in the last 40 min of periods A, B and C as the ratio of glucose infused to maintain hyperglycaemia to prevailing insulin concentrations, was nearly 50% lower in obese subjects (Table 1) .
Total fasting plasma amino acid concentrations were slightly, non-signi®cantly higher in obese compared to non-obese subjects in the basal state and throughout the study (Figure 1 ). The sum of BCAAs was approximately 10% higher in obese subjects (539 (79) mmolal vs 479 (24); P NS). Plasma amino acid levels in obese subjects G Marchesini et al
In the basal, pre-infusion period total plasma amino acid concentrations decreased by 80 ± 100 mmolal in both groups (P NS). During the period of hyperglycaemia with hyperinsulinaemia (period A) the plasma concentration of most amino acids fell signi®cantly and, by 100 min, total plasma amino acid concentrations were reduced by 300 ± 400 mmolal, without differences between groups. In the last 20 min of period A, total plasma amino acids decreased further by nearly 200 mmolal. This reduction was largely due to BCAA decrease, which accounted for 30 ± 40% of total amino acid disappearance (Figure 1) .
During insulin suppression by somatostatin while maintaining hyperglycaemia (period B), total plasma amino acids increased by 300 ± 400 mmolal, without differences between groups. The increase was particularly steep in the last 20 min of such experimental condition. BCAA, phenylalanine and tyrosine, serine, lysine and arginine showed a signi®cant increase (Figures 1 and 2) . At the beginning of period C, total plasma amino acids were on average 300 mmolal lower than those measured at the beginning of the study.
When somatostatin infusion was discontinued, plasma amino acids decreased to a ®nal concentration in the range of 2100 ± 2200 mmolal in both groups. In the last 20 min, total plasma amino acid concentrations fell by approximately 200 ± 250 mmolal, i.e., in a range similar to that observed in period A, without differences between groups.
The plasma concentrations of most amino acids (Figures 1 and 2) showed a time-course similar to that presented for total plasma amino acids concentration. No differences were observed between the two groups.
The net rates of total plasma amino acid disappearance and appearance (Table 2) were similar in obese and non-obese subjects, both in the basal period and during the experimental conditions. In the basal state, the net rate of disappearance of total amino acids from Figure 2 Time-courses of plasma levels of BCAA (valine isoleucine leucine) and aromatic amino acids (tyrosine phenylalanine) during the study in controls (open circles) and in obese subjects (closed circles). An asterisk marks periods of signi®cant amino acid accumulation or disappearance. Data are presented as means AE 2s.e. in mmolal. Table 2 Net rate of amino acid appearance ( ) or disappearance (À) during basal period (from time À30 to À10 min) and in the course of the hyperglycaemic clamp (period A, 100 ± 120 min; period B, 160 ± 180 min; period C, 220 ± 240 min). Signi®cantly different from basal value; P`0.025.
Plasma amino acid levels in obese subjects G Marchesini et al plasma was on average 200 ± 250 mmolal per hour. This value increased to a range of 500 ± 550 mmolal per hour in the last 20 min of period A (hyperglycaemia with hyperinsulinaemia). During insulin suppression by somatostatin infusion (period B), the net rate of plasma amino acids appearance was on average 700 ± 900 mmolal per hour in non-obese. Finally, when somatostatin was discontinued and hyperinsulinaemia resumed (period C), the net rate of plasma amino acids disappearance was in a range of 600 ± 700 mmolal. Also the rates of disappearance and appearance of individual amino acids did not differ in the two groups. In particular, the rate of disappearance of the sum of BCAAs, which are extremely responsive to insulin concentrations, was 34 (27) mmolal per hour in nonobese and 41 (26) in obese subjects in the basal period. This value increased to 156 (60) mmolal per hour and 195 (85), respectively, during period A (P between groups NS). During insulin suppression by somatostatin (period B), the net rate of BCAA appearance was 129 (81) mmolal per hour in nonobese and 210 (38) in obese (P NS). After discontinuing somatostatin infusion, during hyperglycaemia with hyperinsulinaemia and in the presence of a moderate hypoaminoacidaemia (period C), the net rate of disappearance of BCAA was 100 (64) mmolal per hour in nonobese and 159 (84) in obese (P NS).
Discussion
Information about amino acid metabolism in human obesity and its possible involvement in the phenomenon of insulin resistance is scarce and not conclusive. 17, 19, 20, 22 Independent contributors to the phenomenon of insulin resistance in human obesity (e.g. impaired glucose tolerance or diabetes, body fat distribution), as well as differences in the way insulin effects are assessed (e.g. amino acids disappearance from plasma, nitrogen balance, turnover of labelled amino acids, regional artero-venous differences of amino acids) are probably responsible for inconsistent literature data. As to the effects of hyperglycaemia on amino acids metabolism in obesity, information is even poorer. 16 In the present study we found that physiological hyperinsulinaemia during steady-state hyperglycaemia (periods A and C) yields a diminished wholebody glucose metabolism and a lower suppression of plasma FFA in obese patients with normal glucose tolerance, but a normal disappearance of amino acids from plasma. This ®nding suggests that the insulin resistance of glucose and lipid metabolism, a feature of obesity, 29 does not extend to amino acid metabolism. Such a conclusion is in agreement with data recently obtained in nondiabetic obese subjects undergoing a study of leucine turnover during euglycaemic clamp 30 as well as with other data from the literature. 19, 23, 24, 31 The hyperglycaemic clamp technique we used is a suitable tool for evaluating the effects of insulin on plasma amino acids concentrations under physiological or near-physiological conditions characterized by substrate interactions. By this technique plasma glucose can be ®xed at levels supplying the periphery and the liver with glucose to reduce amino acid and FFA consumption (mainly oxidation). In our experimental design plasma glucose was raised and maintained at a level (approximately 11 mmolal), which is only 30% higher than that observed in a healthy man after a meal. Such glucose levels effectively stimulated insulin secretion, and the peak insulin concentrations were close to the values normally attained in response to feeding. Care was taken to examine obese subjects with insulin levels similar to controls. In both groups insulin concentrations were in the range known to suppress hepatic glucose production, including amino acids-derived gluconeogenesis. 32, 33 On the other hand, hyperglycaemia is also known to contribute to the decline of hepatic glucose production, although with mechanisms still poorly understood. 34 Whether the more pronounced decline in plasma amino acids observed during period A of our study, as compared with the basal period, was entirely due to hyperinsulinaemia or to the combination of hyperinsulinaemia and hyperglycaemia cannot be easily understood. Anyway, the disappearance of amino acids from plasma was similar in obese subjects and in controls, suggesting an intact amino acid metabolism in obesity in this experimental condition.
Even assuming that hyperinsulinaemia is the sole driving force in the disappearance of amino acids from plasma in periods A and C, the methods employed in the present study do not allow any inference as to its possible mechanisms. In particular, it is not possible to differentiate whether the decline of plasma amino acid concentration was due to a greater uptake of amino acids in the tissues (e.g. BCAA in skeletal muscle), to a stimulated protein synthesis, or to a suppressed proteolysis. The notion that insulin levels in a range similar to those measured in the present study (350 ± 400 pmolal) in both non-obese and obese subjects, suppressed proteolysis by only 10 ± 15% 30 supports the idea of a prevalent uptake of amino acids from plasma and accumulation in peripheral tissues.
The switch of plasma amino acids from a net disappearance (period A) to a net appearance in the period of hyperglycaemia with basal insulin (period B) deserves a particular comment. In the latter experimental condition, hyperglycaemia alone was not able to maintain the accelerated disappearance of amino acids from plasma observed with hyperinsulinemia (period A and C vs basal state). As a consequence, plasma amino acids rapidly returned towards basal levels. This might be attributed to a prompt decline in the¯ux of amino acids from the extra-cellular Plasma amino acid levels in obese subjects G Marchesini et al compartment to the skeletal muscle (insulin effect on amino acid uptake and accumulation) as well as to an accelerated ef¯ux of amino acids from the muscle tissue (lack of insulin suppression of proteolysis). A net rate of appearance of amino acids in plasma is also consistent with the hypothesis that hyperglycaemia, in the absence of hyperinsulinaemia, could favour proteolysis, 25, 35 but isotopic studies failed to show a speci®c effect of hyperglycaemia on protein metabolism. 36 As an alternative, amino acid appearance in plasma might result from replenished glycogen stores, with lack of amino acid need for glucagon-stimulated gluconeogenesis. 37 Plasma glucagon levels, suppressed by glucose and somatostatin infusion, might be involved in plasma amino acid changes observed in period B. Glucagon suppression by glucose infusion reduced amino acid-derived urea synthesis 38 and when somatostatin was infused in normal subjects, plasma amino acids increased and urea synthesis declined. 39, 40 However, plasma glucose levels were not controlled for in these experiments, whereas the level of hyperglycaemia was clamped in the present study. Glucagon also exerts a direct stimulus on proteolysis, further contributing to changes in plasma amino acids. 41 In the present study, plasma glucagon was similar between groups throughout the whole experimental period. Therefore, whatever the mechanism of amino acid regulation during period B (glucose, insulin or glucagon), we can conclude that a normal response of amino acid metabolism during this experimental set-up is also maintained in obese subjects.
Therefore, normal rates of disappearance and appearance of plasma amino acids were found in all the experimental conditions we tested, i.e. overnight fasting and hyperglycaemia withawithout hyperinsulinaemia, and independent of amino acid concentrations. Therefore, the net traf®c of amino acids to and from different tissues in relation to hormonal and nonhormonal drives is not impaired in human obesity. This holds true either when the¯ow of amino acids is directed from the extracellular compartment to the liver to feed gluconeogenesis, or when it is mainly directed towards the skeletal muscle to be used for protein synthesis. Obesity-related differences in regional metabolism of amino acids (liver vs skeletal muscle vs other tissues) are unlikely, but only organ balance studies with the assessment of regional arterovenous differences can de®nitely conclude for an intact whole-body amino acids metabolism.
The conclusion that amino acid metabolism is not altered in obese subjects with normal glucose tolerance, even in the presence of insulin resistance involving glucose and FFA metabolism, extends to a variety of clinical and experimental conditions, including overnight fasting, and may have clinical implications during nutritional interventions. Also the effect of hyperglycaemia on amino acid metabolism, if any, is not altered in human obesity. Con®rmation studies with tracers and organ balance studies are needed.
